Adagene, Inc. (ADAG)
| Market Cap | 974.78M |
| Revenue (ttm) | 790,000 |
| Net Income (ttm) | -34,243 |
| Shares Out | 42.33M |
| EPS (ttm) | 0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $23.11 |
| Previous Close | $22.99 |
| Change ($) | 0.12 |
| Change (%) | 0.52% |
| Day's Open | 22.85 |
| Day's Range | 22.00 - 23.18 |
| Day's Volume | 70,573 |
| 52-Week Range | 20.21 - 31.83 |
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming...
SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to tran...
Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s SAFEbody™ technology platform...
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering.
Adagene, Inc. has filed to go public with an IPO on the NASDAQ.
Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment,...
Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.
About ADAG
Adagene, a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for th... [Read more...]
| Industry Biotechnology | IPO Date Feb 9, 2021 |
| CEO Peter (Peizhi) Luo, Ph.D. | Employees 199 |
| Stock Exchange NASDAQ | Ticker Symbol ADAG |
Financial Performance
In 2019, Adagene's revenue was $480,000, a decrease of -68.24% compared to the previous year's $1.51 million. Losses were -$16.43 million, 7.64% more than in 2018.